{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T01:05:39Z","timestamp":1793840739490,"version":"4.6.1"},"reference-count":84,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T00:00:00Z","timestamp":1776643200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T00:00:00Z","timestamp":1776643200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Impot Res"],"DOI":"10.1038\/s41443-026-01271-2","type":"journal-article","created":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T08:31:14Z","timestamp":1776673874000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Sexual and urinary outcomes of minimally invasive surgical therapies for LUTS\/BPH: a narrative review"],"prefix":"10.1038","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9945-5686","authenticated-orcid":false,"given":"Ahmet Tevfik","family":"Albayrak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1526-2065","authenticated-orcid":false,"given":"Muhammet Volkan","family":"Bulbul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8149-2825","authenticated-orcid":false,"given":"Andre","family":"Rubez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6853-1014","authenticated-orcid":false,"given":"Adriano","family":"Fregonesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2530-7012","authenticated-orcid":false,"given":"Ege Can","family":"Serefoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,20]]},"reference":[{"key":"1271_CR1","doi-asserted-by":"publisher","first-page":"28","DOI":"10.22514\/jomh.2024.183","volume":"20","author":"YH Choi","year":"2024","unstructured":"Choi YH. Euodia rutaecarpa fruit attenuates testosterone-induced benign prostatic hyperplasia in rats by inhibiting 5\u03b1-reductase activity and androgen receptor signaling pathway. J Mens Health. 2024;20:28\u201337.","journal-title":"J Mens Health"},{"key":"1271_CR2","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/s10020-023-00734-2","volume":"29","author":"S Shan","year":"2023","unstructured":"Shan S, Su M, Li Y, Wang Z, Liu D, Zhou Y, et al. Mechanism of RhoA regulating benign prostatic hyperplasia: RhoA-ROCK-\u03b2-catenin signaling axis and static & dynamic dual roles. Mol Med. 2023;29:139.","journal-title":"Mol Med"},{"key":"1271_CR3","doi-asserted-by":"publisher","first-page":"11634","DOI":"10.3390\/ijms241411634","volume":"24","author":"J Hata","year":"2023","unstructured":"Hata J, Harigane Y, Matsuoka K, Akaihata H, Yaginuma K, Meguro S, et al. Mechanism of androgen-independent stromal proliferation in benign prostatic hyperplasia. Int J Mol Sci. 2023;24:11634.","journal-title":"Int J Mol Sci"},{"key":"1271_CR4","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1159\/000052475","volume":"39","author":"JB Anderson","year":"2001","unstructured":"Anderson JB, Roehrborn CG, Schalken JA, Emberton M. The progression of benign prostatic hyperplasia: examining the evidence and determining the risk. Eur Urol. 2001;39:390\u20139.","journal-title":"Eur Urol"},{"key":"1271_CR5","unstructured":"Vuichoud C, Loughlin KR. Benign prostatic hyperplasia: epidemiology, economics and evaluation. Can J Urol. 2015;22 1\u20136."},{"key":"1271_CR6","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1111\/j.1464-410X.2005.05831.x","volume":"96","author":"MK Li","year":"2005","unstructured":"Li MK, Garcia LA, Rosen R. Lower urinary tract symptoms and male sexual dysfunction in Asia: a survey of ageing men from five Asian countries. BJU Int. 2005;96:1339\u201354.","journal-title":"BJU Int"},{"key":"1271_CR7","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/j.eururo.2003.08.015","volume":"44","author":"R Rosen","year":"2003","unstructured":"Rosen R, Altwein J, Boyle P, Kirby RS, Lukacs B, Meuleman E, et al. Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur Urol. 2003;44:637\u201349.","journal-title":"Eur Urol"},{"key":"1271_CR8","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1007\/s11255-008-9386-z","volume":"40","author":"A Ozayar","year":"2008","unstructured":"Ozayar A, Zumrutbas AE, Yaman O. The relationship between lower urinary tract symptoms (LUTS), diagnostic indicators of benign prostatic hyperplasia (BPH), and erectile dysfunction in patients with moderate to severely symptomatic BPH. Int Urol Nephrol. 2008;40:933\u20139.","journal-title":"Int Urol Nephrol"},{"key":"1271_CR9","first-page":"272","volume":"31","author":"F Calais Da Silva","year":"1997","unstructured":"Calais Da Silva F, Marquis P, Deschaseaux P, Gineste JL, Cauquil J, Patrick DL. Relative importance of sexuality and quality of life in patients with prostatic symptoms. Results an Int study Eur Urol. 1997;31:272\u201380.","journal-title":"Results an Int study Eur Urol"},{"key":"1271_CR10","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.euf.2022.03.008","volume":"8","author":"I Sokolakis","year":"2022","unstructured":"Sokolakis I, Pyrgidis N, Russo GI, Sountoulides P, Hatzichristodoulou G. Preserving ejaculation: a guide through the landscape of interventional and surgical options for benign prostatic obstruction. Eur Urol Focus. 2022;8:380\u20133.","journal-title":"Eur Urol Focus"},{"key":"1271_CR11","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1016\/j.eururo.2005.12.042","volume":"50","author":"J Rassweiler","year":"2006","unstructured":"Rassweiler J, Teber D, Kuntz R, Hofmann R. Complications of transurethral resection of the prostate (TURP)-incidence, management, and prevention. Eur Urol. 2006;50:969\u201379.","journal-title":"Eur Urol"},{"key":"1271_CR12","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1046\/j.1464-4096.2001.01817.x","volume":"89","author":"HH Leliefeld","year":"2002","unstructured":"Leliefeld HH, Stoevelaar HJ, McDonnell J. Sexual function before and after various treatments for symptomatic benign prostatic hyperplasia. BJU Int. 2002;89:208\u201313.","journal-title":"BJU Int"},{"key":"1271_CR13","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/j.eururo.2020.12.019","volume":"79","author":"S Malde","year":"2021","unstructured":"Malde S, Umbach R, Wheeler JR, Lytvyn L, Cornu JN, Gacci M, et al. A systematic review of patients\u2019 values, preferences, and expectations for the diagnosis and treatment of male lower urinary tract symptoms. Eur Urol. 2021;79:796\u2013809.","journal-title":"Eur Urol"},{"key":"1271_CR14","doi-asserted-by":"crossref","unstructured":"Pace KJC, Li T, Elterman DS. Next-gen minimally invasive surgical therapies for benign prostatic hyperplasia: innovations, selection, and best practices- a review from European Association of Urology endourology. Curr Opin Urol. 2025.","DOI":"10.1097\/MOU.0000000000001335"},{"key":"1271_CR15","doi-asserted-by":"publisher","first-page":"110","DOI":"10.3390\/biomedicines12010110","volume":"12","author":"A Kaltsas","year":"2024","unstructured":"Kaltsas A, Kratiras Z, Zachariou A, Dimitriadis F, Sofikitis N, Chrisofos M. Evaluating the impact of benign prostatic hyperplasia surgical treatments on sexual health. Biomedicines. 2024;12:110.","journal-title":"Biomedicines"},{"key":"1271_CR16","first-page":"12003","volume":"95","author":"R Leonardi","year":"2023","unstructured":"Leonardi R, Ambrosini F, Malinaric R, Cafarelli A, Calarco A, Colombo R, et al. New minimally invasive solutions for benign prostatic obstruction (BPO) management: a position paper from the UrOP (Urologi Ospedalita Gestione Privata). Arch Ital Urol Androl. 2023;95:12003.","journal-title":"Arch Ital Urol Androl"},{"key":"1271_CR17","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1055\/a-2269-1280","volume":"55","author":"C Netsch","year":"2024","unstructured":"Netsch C, Gross AJ, Herrmann TR, Herrmann J, Becker B. [Minimally-Invasive surgical techniques (MIST): shedding light on the mist]. Aktuelle Urol. 2024;55:219\u201327.","journal-title":"Aktuelle Urol"},{"key":"1271_CR18","doi-asserted-by":"publisher","first-page":"59","DOI":"10.3390\/surgeries6030059","volume":"6","author":"G Colalillo","year":"2025","unstructured":"Colalillo G, Ippoliti S, Asimakopoulos AD. A systematic review of the optilume\u00ae drug-coated balloon in the management of LUTS secondary to BPH and urethral stricture. Surgeries. 2025;6:59.","journal-title":"Surgeries"},{"key":"1271_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s41073-019-0064-8","volume":"4","author":"C Baethge","year":"2019","unstructured":"Baethge C, Goldbeck-Wood S, Mertens S. SANRA-a scale for the quality assessment of narrative review articles. Res Integr Peer Rev. 2019;4:5.","journal-title":"Res Integr Peer Rev"},{"key":"1271_CR20","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1111\/bju.12982","volume":"116","author":"F Porpiglia","year":"2015","unstructured":"Porpiglia F, Fiori C, Bertolo R, Garrou D, Cattaneo G, Amparore D. Temporary implantable nitinol device (TIND): a novel, minimally invasive treatment for relief of lower urinary tract symptoms (LUTS) related to benign prostatic hyperplasia (BPH): feasibility, safety and functional results at 1 year of follow-up. BJU Int. 2015;116:278\u201387.","journal-title":"BJU Int"},{"key":"1271_CR21","first-page":"1549","volume":"148","author":"MJ Barry","year":"1992","unstructured":"Barry MJ, Fowler FJ Jr., O\u2019Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK, et al. The American Urological Association symptom index for benign prostatic hyperplasia. Meas Comm Am Urological Association J Urol. 1992;148:1549\u201357.","journal-title":"Meas Comm Am Urological Association J Urol"},{"key":"1271_CR22","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1007\/s00345-020-03418-2","volume":"39","author":"C De Nunzio","year":"2021","unstructured":"De Nunzio C, Cantiello F, Fiori C, Crocerossa F, Tognoni P, Amparore D, et al. Urinary and sexual function after treatment with temporary implantable nitinol device (iTind) in men with LUTS: 6-month interim results of the MT-06-study. World J Urol. 2021;39:2037\u201342.","journal-title":"World J Urol"},{"key":"1271_CR23","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/s41391-020-00281-5","volume":"24","author":"D Amparore","year":"2021","unstructured":"Amparore D, Fiori C, Valerio M, Schulman C, Giannakis I, De Cillis S, et al. 3-Year results following treatment with the second generation of the temporary implantable nitinol device in men with LUTS secondary to benign prostatic obstruction. Prostate Cancer Prostatic Dis. 2021;24:349\u201357.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"1271_CR24","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1111\/bju.14141","volume":"122","author":"F Porpiglia","year":"2018","unstructured":"Porpiglia F, Fiori C, Bertolo R, Giordano A, Checcucci E, Garrou D, et al. 3-Year follow-up of temporary implantable nitinol device implantation for the treatment of benign prostatic obstruction. BJU Int. 2018;122:106\u201312.","journal-title":"BJU Int"},{"key":"1271_CR25","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1111\/bju.14608","volume":"123","author":"F Porpiglia","year":"2019","unstructured":"Porpiglia F, Fiori C, Amparore D, Kadner G, Manit A, Valerio M, et al. Second-generation of temporary implantable nitinol device for the relief of lower urinary tract symptoms due to benign prostatic hyperplasia: results of a prospective, multicentre study at 1 year of follow-up. BJU Int. 2019;123:1061\u20139.","journal-title":"BJU Int"},{"key":"1271_CR26","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1089\/end.2022.0226","volume":"37","author":"D Elterman","year":"2023","unstructured":"Elterman D, Alshak MN, Martinez Diaz S, Shore N, Gittleman M, Motola J, et al. An evaluation of sexual function in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia in men treated with the temporarily implanted nitinol device. J Endourol. 2023;37:74\u20139.","journal-title":"J Endourol"},{"key":"1271_CR27","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/sj.ijir.3901327","volume":"17","author":"JC Cappelleri","year":"2005","unstructured":"Cappelleri JC, Rosen RC. The sexual health inventory for men (SHIM): a 5-year review of research and clinical experience. Int J Impot Res. 2005;17:307\u201319.","journal-title":"Int J Impot Res"},{"key":"1271_CR28","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/j.urology.2004.04.056","volume":"64","author":"RC Rosen","year":"2004","unstructured":"Rosen RC, Catania J, Pollack L, Althof S, O\u2019Leary M, Seftel AD. Male Sexual Health Questionnaire (MSHQ): scale development and psychometric validation. Urology. 2004;64:777\u201382.","journal-title":"Urology"},{"key":"1271_CR29","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1111\/j.1464-410X.2011.10342.x","volume":"108","author":"HH Woo","year":"2011","unstructured":"Woo HH, Chin PT, McNicholas TA, Gill HS, Plante MK, Bruskewitz RC, et al. Safety and feasibility of the prostatic urethral lift: a novel, minimally invasive treatment for lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH). BJU Int. 2011;108:82\u20138.","journal-title":"BJU Int"},{"key":"1271_CR30","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1111\/j.1743-6109.2011.02568.x","volume":"9","author":"HH Woo","year":"2012","unstructured":"Woo HH, Bolton DM, Laborde E, Jack G, Chin PT, Rashid P, et al. Preservation of sexual function with the prostatic urethral lift: a novel treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Sex Med. 2012;9:568\u201375.","journal-title":"J Sex Med"},{"key":"1271_CR31","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.urology.2011.10.021","volume":"79","author":"PT Chin","year":"2012","unstructured":"Chin PT, Bolton DM, Jack G, Rashid P, Thavaseelan J, Yu RJ, et al. Prostatic urethral lift: two-year results after treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia. Urology. 2012;79:5\u201311.","journal-title":"Urology"},{"key":"1271_CR32","first-page":"8802","volume":"24","author":"CG Roehrborn","year":"2017","unstructured":"Roehrborn CG, Barkin J, Gange SN, Shore ND, Giddens JL, Bolton DM, et al. Five year results of the prospective randomized controlled prostatic urethral L.I.F.T. study. Can J Urol. 2017;24:8802\u201313.","journal-title":"Can J Urol"},{"key":"1271_CR33","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.eururo.2015.04.024","volume":"68","author":"J Sonksen","year":"2015","unstructured":"Sonksen J, Barber NJ, Speakman MJ, Berges R, Wetterauer U, Greene D, et al. Prospective, randomized, multinational study of prostatic urethral lift versus transurethral resection of the prostate: 12-month results from the BPH6 study. Eur Urol. 2015;68:643\u201352.","journal-title":"Eur Urol"},{"key":"1271_CR34","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1111\/bju.13714","volume":"119","author":"C Gratzke","year":"2017","unstructured":"Gratzke C, Barber N, Speakman MJ, Berges R, Wetterauer U, Greene D, et al. Prostatic urethral lift vs transurethral resection of the prostate: 2-year results of the BPH6 prospective, multicentre, randomized study. BJU Int. 2017;119:767\u201375.","journal-title":"BJU Int"},{"key":"1271_CR35","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1007\/s00345-018-2494-1","volume":"37","author":"KD Sievert","year":"2019","unstructured":"Sievert KD, Schonthaler M, Berges R, Toomey P, Drager D, Herlemann A, et al. Minimally invasive prostatic urethral lift (PUL) efficacious in TURP candidates: a multicenter German evaluation after 2 years. World J Urol. 2019;37:1353\u201360.","journal-title":"World J Urol"},{"key":"1271_CR36","volume":"5","author":"JH Jung","year":"2019","unstructured":"Jung JH, Reddy B, McCutcheon KA, Borofsky M, Narayan V, Kim MH, et al. Prostatic urethral lift for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia. Cochrane Database Syst Rev. 2019;5:CD012832.","journal-title":"Cochrane Database Syst Rev"},{"key":"1271_CR37","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/s41391-018-0118-x","volume":"22","author":"D Rukstalis","year":"2019","unstructured":"Rukstalis D, Grier D, Stroup SP, Tutrone R, deSouza E, Freedman S, et al. Prostatic Urethral Lift (PUL) for obstructive median lobes: 12 month results of the MedLift Study. Prostate Cancer Prostatic Dis. 2019;22:411\u20139.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"1271_CR38","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1097\/JU.0000000000001132","volume":"204","author":"LE Miller","year":"2020","unstructured":"Miller LE, Chughtai B, Dornbier RA, McVary KT. Surgical reintervention rate after prostatic urethral lift: systematic review and meta-analysis involving over 2000 patients. J Urol. 2020;204:1019\u201326.","journal-title":"J Urol"},{"key":"1271_CR39","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1016\/j.urology.2015.05.046","volume":"86","author":"C Dixon","year":"2015","unstructured":"Dixon C, Cedano ER, Pacik D, Vit V, Varga G, Wagrell L, et al. Efficacy and safety of rezum system water vapor treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia. Urology. 2015;86:1042\u20137.","journal-title":"Urology"},{"key":"1271_CR40","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1016\/j.juro.2015.10.181","volume":"195","author":"KT McVary","year":"2016","unstructured":"McVary KT, Gange SN, Gittelman MC, Goldberg KA, Patel K, Shore ND, et al. Minimally invasive prostate convective water vapor energy ablation: a multicenter, randomized, controlled study for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol. 2016;195:1529\u201338.","journal-title":"J Urol"},{"key":"1271_CR41","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1016\/j.juro.2016.12.045","volume":"197","author":"CG Roehrborn","year":"2017","unstructured":"Roehrborn CG, Gange SN, Gittelman MC, Goldberg KA, Patel K, Shore ND, et al. Convective thermal therapy: durable 2-year results of randomized controlled and prospective crossover studies for treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. J Urol. 2017;197:1507\u201316.","journal-title":"J Urol"},{"key":"1271_CR42","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.urology.2018.12.041","volume":"126","author":"KT McVary","year":"2019","unstructured":"McVary KT, Rogers T, Roehrborn CG. Rezum water vapor thermal therapy for lower urinary tract symptoms associated with benign prostatic hyperplasia: 4-year results from randomized controlled study. Urology. 2019;126:171\u20139.","journal-title":"Urology"},{"key":"1271_CR43","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1097\/JU.0000000000001778","volume":"206","author":"KT McVary","year":"2021","unstructured":"McVary KT, Gittelman MC, Goldberg KA, Patel K, Shore ND, Levin RM, et al. Final 5-Year outcomes of the multicenter randomized sham-controlled trial of a water vapor thermal therapy for treatment of moderate to severe lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol. 2021;206:715\u201324.","journal-title":"J Urol"},{"key":"1271_CR44","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1016\/j.jsxm.2018.10.006","volume":"15","author":"KT McVary","year":"2018","unstructured":"McVary KT, Rogers T, Mahon J, Gupta NK. Is sexual function better preserved after water vapor thermal therapy or medical therapy for lower urinary tract symptoms due to benign prostatic hyperplasia? J Sex Med. 2018;15:1728\u201338.","journal-title":"J Sex Med"},{"key":"1271_CR45","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1038\/sj.ijir.3900472","volume":"11","author":"RC Rosen","year":"1999","unstructured":"Rosen RC, Cappelleri JC, Smith MD, Lipsky J, Pena BM. Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res. 1999;11:319\u201326.","journal-title":"Int J Impot Res"},{"key":"1271_CR46","first-page":"159","volume":"9","author":"MF Darson","year":"2017","unstructured":"Darson MF, Alexander EE, Schiffman ZJ, Lewitton M, Light RA, Sutton MA, et al. Procedural techniques and multicenter postmarket experience using minimally invasive convective radiofrequency thermal therapy with Rezum system for treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. Res Rep Urol. 2017;9:159\u201368.","journal-title":"Res Rep Urol"},{"key":"1271_CR47","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1089\/end.2014.0304","volume":"29","author":"K Faber","year":"2015","unstructured":"Faber K, de Abreu AL, Ramos P, Aljuri N, Mantri S, Gill I, et al. Image-guided robot-assisted prostate ablation using water jet-hydrodissection: initial study of a novel technology for benign prostatic hyperplasia. J Endourol. 2015;29:63\u20139.","journal-title":"J Endourol"},{"key":"1271_CR48","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1038\/s41443-019-0158-3","volume":"31","author":"G Reale","year":"2019","unstructured":"Reale G, Cimino S, Bruno G, Palmieri F, Giardina R, Russo GI, et al. \u201cAquabeam(R) System\u201d for benign prostatic hyperplasia and LUTS: birth of a new era. a systematic review of functional and sexual outcome and adverse events of the technique. Int J Impot Res. 2019;31:392\u20139.","journal-title":"Int J Impot Res"},{"key":"1271_CR49","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1111\/bju.13358","volume":"117","author":"P Gilling","year":"2016","unstructured":"Gilling P, Reuther R, Kahokehr A, Fraundorfer M. Aquablation - image-guided robot-assisted waterjet ablation of the prostate: initial clinical experience. BJU Int. 2016;117:923\u20139.","journal-title":"BJU Int"},{"key":"1271_CR50","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1016\/j.juro.2017.01.056","volume":"197","author":"P Gilling","year":"2017","unstructured":"Gilling P, Anderson P, Tan A. Aquablation of the prostate for symptomatic benign prostatic hyperplasia: 1-year results. J Urol. 2017;197:1565\u201372.","journal-title":"J Urol"},{"key":"1271_CR51","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1111\/bju.14126","volume":"121","author":"MM Desai","year":"2018","unstructured":"Desai MM, Singh A, Abhishek S, Laddha A, Pandya H, Ashrafi AN, et al. Aquablation therapy for symptomatic benign prostatic hyperplasia: a single-centre experience in 47 patients. BJU Int. 2018;121:945\u201351.","journal-title":"BJU Int"},{"key":"1271_CR52","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1016\/j.juro.2017.12.065","volume":"199","author":"P Gilling","year":"2018","unstructured":"Gilling P, Barber N, Bidair M, Anderson P, Sutton M, Aho T, et al. WATER: a double-blind, randomized, controlled trial of aquablation((R)) vs transurethral resection of the prostate in benign prostatic hyperplasia. J Urol. 2018;199:1252\u201361.","journal-title":"J Urol"},{"key":"1271_CR53","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1111\/bju.14360","volume":"123","author":"M Desai","year":"2019","unstructured":"Desai M, Bidair M, Bhojani N, Trainer A, Arther A, Kramolowsky E, et al. WATER II (80-150 mL) procedural outcomes. BJU Int. 2019;123:106\u201312.","journal-title":"BJU Int"},{"key":"1271_CR54","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1007\/s12325-019-00952-3","volume":"36","author":"P Gilling","year":"2019","unstructured":"Gilling P, Barber N, Bidair M, Anderson P, Sutton M, Aho T, et al. Two-Year outcomes after aquablation compared to TURP: efficacy and ejaculatory improvements sustained. Adv Ther. 2019;36:1326\u201336.","journal-title":"Adv Ther"},{"key":"1271_CR55","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/s41443-018-0045-3","volume":"30","author":"FA Yafi","year":"2018","unstructured":"Yafi FA, Tallman CT, Seard ML, Jordan ML. Aquablation outcomes for the U.S. cohort of men with LUTS due to BPH in large prostates (80-150 cc). Int J Ipot Res. 2018;30:209\u201314.","journal-title":"Int J Ipot Res"},{"key":"1271_CR56","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/s41443-025-01087-6","volume":"38","author":"A Bettencourt","year":"2025","unstructured":"Bettencourt A, Wu J, Borrell JA, Furtado TP, Mills JN, Jayadevan R, et al. Ejaculatory function after robotic waterjet ablation for the treatment of benign prostatic hyperplasia: a systematic review. Int J Ipot Res. 2025;38:67\u201375.","journal-title":"Int J Ipot Res"},{"key":"1271_CR57","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/s41391-019-0196-4","volume":"23","author":"CM Pacella","year":"2020","unstructured":"Pacella CM, Patelli G, Iapicca G, Manenti G, Perretta T, Ryan CP, et al. Transperineal laser ablation for percutaneous treatment of benign prostatic hyperplasia: a feasibility study. Results at 6 and 12 months from a retrospective multi-centric study. Prostate Cancer Prostatic Dis. 2020;23:356\u201363.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"1271_CR58","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1007\/s00345-024-05077-z","volume":"42","author":"M Lo Re","year":"2024","unstructured":"Lo Re M, Polverino P, Rivetti A, Pecoraro A, Saladino M, Pezzoli M, et al. Transperineal laser ablation (TPLA) of the prostate for benign prostatic obstruction: the first 100 patients cohort of a prospective, single-center study. World J Urol. 2024;42:402.","journal-title":"World J Urol"},{"key":"1271_CR59","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1111\/bju.16008","volume":"132","author":"R Bertolo","year":"2023","unstructured":"Bertolo R, Iacovelli V, Cipriani C, Carilli M, Vittori M, Antonucci M, et al. Ejaculatory function following transperineal laser ablation vs TURP for benign prostatic obstruction: a randomized trial. BJU Int. 2023;132:100\u20138.","journal-title":"BJU Int"},{"key":"1271_CR60","doi-asserted-by":"publisher","DOI":"10.1177\/17562872231198634","volume":"15","author":"L Tzelves","year":"2023","unstructured":"Tzelves L, Nagasubramanian S, Pinitas A, Juliebo-Jones P, Madaan S, Sienna G, et al. Transperineal laser ablation as a new minimally invasive surgical therapy for benign prostatic hyperplasia: a systematic review of existing literature. Ther Adv Urol. 2023;15:17562872231198634.","journal-title":"Ther Adv Urol"},{"key":"1271_CR61","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/S0022-5347(17)59339-8","volume":"115","author":"ME Mitchell","year":"1976","unstructured":"Mitchell ME, Waltman AC, Athanasoulis CA, Kerr WS Jr., Dretler SP. Control of massive prostatic bleeding with angiographic techniques. J Urol. 1976;115:692\u20135.","journal-title":"J Urol"},{"key":"1271_CR62","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s00270-015-1238-5","volume":"39","author":"F Sun","year":"2016","unstructured":"Sun F, Crisostomo V, Baez-Diaz C, Sanchez FM. Prostatic artery embolization (PAE) for symptomatic benign prostatic hyperplasia (BPH): part 2, insights into the technical rationale. Cardiovasc Intervent Radiol. 2016;39:161\u20139.","journal-title":"Cardiovasc Intervent Radiol"},{"key":"1271_CR63","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1590\/S1677-5538.IBJU.2013.02.11","volume":"39","author":"G Camara-Lopes","year":"2013","unstructured":"Camara-Lopes G, Mattedi R, Antunes AA, Carnevale FC, Cerri GG, Srougi M, et al. The histology of prostate tissue following prostatic artery embolization for the treatment of benign prostatic hyperplasia. Int Braz J Urol. 2013;39:222\u20137.","journal-title":"Int Braz J Urol"},{"key":"1271_CR64","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s00270-009-9727-z","volume":"33","author":"FC Carnevale","year":"2010","unstructured":"Carnevale FC, Antunes AA, da Motta Leal Filho JM, de Oliveira Cerri LM, Baroni RH, Marcelino AS, et al. Prostatic artery embolization as a primary treatment for benign prostatic hyperplasia: preliminary results in two patients. Cardiovasc Intervent Radiol. 2010;33:355\u201361.","journal-title":"Cardiovasc Intervent Radiol"},{"key":"1271_CR65","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.jvir.2010.09.030","volume":"22","author":"JM Pisco","year":"2011","unstructured":"Pisco JM, Pinheiro LC, Bilhim T, Duarte M, Mendes JR, Oliveira AG. Prostatic arterial embolization to treat benign prostatic hyperplasia. J Vasc Interv Radiol. 2011;22:11\u20139.","journal-title":"J Vasc Interv Radiol"},{"key":"1271_CR66","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1007\/s00270-013-0739-3","volume":"36","author":"AM Moreira","year":"2013","unstructured":"Moreira AM, Marques CFS, Antunes AA, Nahas CSR, Nahas SC, de Gregorio Ariza MA, et al. Transient ischemic rectitis as a potential complication after prostatic artery embolization: case report and review of the literature. Cardiovasc Intervent Radiol. 2013;36:1690\u20134.","journal-title":"Cardiovasc Intervent Radiol"},{"key":"1271_CR67","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1007\/s00270-015-1083-6","volume":"38","author":"A Laborda","year":"2015","unstructured":"Laborda A, De Assis AM, Ioakeim I, Sanchez-Ballestin M, Carnevale FC, De Gregorio MA. Radiodermitis after prostatic artery embolization: case report and review of the literature. Cardiovasc Intervent Radiol. 2015;38:755\u20139.","journal-title":"Cardiovasc Intervent Radiol"},{"key":"1271_CR68","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1016\/j.jvir.2016.06.017","volume":"27","author":"N Kisilevzky","year":"2016","unstructured":"Kisilevzky N, Laudanna Neto C, Cividanes A. Ischemia of the glans penis following prostatic artery embolization. J Vasc Interv Radiol. 2016;27:1745\u20137.","journal-title":"J Vasc Interv Radiol"},{"key":"1271_CR69","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1016\/j.jvir.2019.05.033","volume":"30","author":"R Ayyagari","year":"2019","unstructured":"Ayyagari R, Powell T, Staib L, Chapiro J, Schoenberger S, Devito R, et al. Case-Control comparison of conventional end-hole versus balloon-occlusion microcatheter prostatic artery embolization for treatment of symptomatic benign prostatic hyperplasia. J Vasc Interv Radiol. 2019;30:1459\u201370.","journal-title":"J Vasc Interv Radiol"},{"key":"1271_CR70","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1016\/j.jvir.2020.02.029","volume":"31","author":"SZ Maron","year":"2020","unstructured":"Maron SZ, Cedillo MA, Sher A, Kim J, Fischman AM. Use of 70\u2212\u2013150-mum radiopaque spherical embolics for prostatic artery embolization. J Vasc Interv Radiol. 2020;31:1084\u20139.","journal-title":"J Vasc Interv Radiol"},{"key":"1271_CR71","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1148\/radiol.2020191249","volume":"296","author":"FC Carnevale","year":"2020","unstructured":"Carnevale FC, Moreira AM, de Assis AM, Antunes AA, Cristina de Paula Rodrigues V, Srougi M, et al. Prostatic artery embolization for the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia: 10 years\u2019 experience. Radiology. 2020;296:444\u201351.","journal-title":"Radiology"},{"key":"1271_CR72","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.urology.2015.04.037","volume":"86","author":"GI Russo","year":"2015","unstructured":"Russo GI, Kurbatov D, Sansalone S, Lepetukhin A, Dubsky S, Sitkin I, et al. Prostatic arterial embolization vs open prostatectomy: a 1-year matched-pair analysis of functional outcomes and morbidities. Urology. 2015;86:343\u20138.","journal-title":"Urology"},{"key":"1271_CR73","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s00270-015-1202-4","volume":"39","author":"FC Carnevale","year":"2016","unstructured":"Carnevale FC, Iscaife A, Yoshinaga EM, Moreira AM, Antunes AA, Srougi M. Transurethral resection of the prostate (TURP) versus original and PErFecTED prostate artery embolization (PAE) due to benign prostatic hyperplasia (BPH): preliminary results of a single center, prospective, urodynamic-controlled analysis. Cardiovasc Intervent Radiol. 2016;39:44\u201352.","journal-title":"Cardiovasc Intervent Radiol"},{"key":"1271_CR74","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1111\/bju.14249","volume":"122","author":"AF Ray","year":"2018","unstructured":"Ray AF, Powell J, Speakman MJ, Longford NT, DasGupta R, Bryant T, et al. Efficacy and safety of prostate artery embolization for benign prostatic hyperplasia: an observational study and propensity-matched comparison with transurethral resection of the prostate (the UK-ROPE study). BJU Int. 2018;122:270\u201382.","journal-title":"BJU Int"},{"key":"1271_CR75","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1016\/j.jvir.2019.12.810","volume":"31","author":"I Insausti","year":"2020","unstructured":"Insausti I, Saez de Ocariz A, Galbete A, Capdevila F, Solchaga S, Giral P, et al. Randomized comparison of prostatic artery embolization versus transurethral resection of the prostate for treatment of benign prostatic hyperplasia. J Vasc Interv Radiol. 2020;31:882\u201390.","journal-title":"J Vasc Interv Radiol"},{"key":"1271_CR76","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1148\/radiol.13122803","volume":"270","author":"YA Gao","year":"2014","unstructured":"Gao YA, Huang Y, Zhang R, Yang YD, Zhang Q, Hou M, et al. Benign prostatic hyperplasia: prostatic arterial embolization versus transurethral resection of the prostate-a prospective, randomized, and controlled clinical trial. Radiology. 2014;270:920\u20138.","journal-title":"Radiology"},{"key":"1271_CR77","doi-asserted-by":"publisher","first-page":"k2338","DOI":"10.1136\/bmj.k2338","volume":"361","author":"D Abt","year":"2018","unstructured":"Abt D, Hechelhammer L, Mullhaupt G, Markart S, Gusewell S, Kessler TM, et al. Comparison of prostatic artery embolisation (PAE) versus transurethral resection of the prostate (TURP) for benign prostatic hyperplasia: randomised, open label, non-inferiority trial. BMJ. 2018;361:k2338.","journal-title":"BMJ"},{"key":"1271_CR78","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.eururo.2019.11.010","volume":"77","author":"JM Pisco","year":"2020","unstructured":"Pisco JM, Bilhim T, Costa NV, Torres D, Pisco J, Pinheiro LC, et al. Randomised clinical trial of prostatic artery embolisation versus a sham procedure for benign prostatic hyperplasia. Eur Urol. 2020;77:354\u201362.","journal-title":"Eur Urol"},{"key":"1271_CR79","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1007\/s00345-019-03044-7","volume":"38","author":"XJ Xu","year":"2020","unstructured":"Xu XJ, Li J, Huang XZ, Liu Q. An updated meta-analysis of prostatic arterial embolization versus transurethral resection of the prostate in the treatment of benign prostatic hyperplasia. World J Urol. 2020;38:2455\u201368.","journal-title":"World J Urol"},{"key":"1271_CR80","doi-asserted-by":"publisher","first-page":"2595","DOI":"10.1007\/s00345-019-03036-7","volume":"38","author":"G Mullhaupt","year":"2020","unstructured":"Mullhaupt G, Hechelhammer L, Diener PA, Engeler DS, Gusewell S, Schmid HP, et al. Ejaculatory disorders after prostatic artery embolization: a reassessment of two prospective clinical trials. World J Urol. 2020;38:2595\u20139.","journal-title":"World J Urol"},{"key":"1271_CR81","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1038\/s41391-021-00362-z","volume":"24","author":"SA Kaplan","year":"2021","unstructured":"Kaplan SA, Pichardo M, Rijo E, Espino G, Lay RR, Estrella R. One-year outcomes after treatment with a drug-coated balloon catheter system for lower urinary tract symptoms related to benign prostatic hyperplasia. Prostate Cancer Prostatic Dis. 2021;24:1073\u20139.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"1271_CR82","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1097\/JU.0000000000003568","volume":"210","author":"SA Kaplan","year":"2023","unstructured":"Kaplan SA, Moss J, Freedman S, Coutinho K, Wu N, Efros M, et al. The PINNACLE study: a double-blind, randomized, sham-controlled study evaluating the optilume BPH catheter system for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol. 2023;210:500\u20139.","journal-title":"J Urol"},{"key":"1271_CR83","unstructured":"Cornu JN, Gacci M, Gratzke C, Herrmann TRW, Madersbacher S, Mamoulakis C, et al. EAU guidelines on non-neurogenic male lower urinary tract symptoms (LUTS), including benign prostatic obstruction (BPO). Eur Urol. 2024;85."},{"key":"1271_CR84","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1097\/JU.0000000000003488.03","volume":"210","author":"JS Sandhu","year":"2023","unstructured":"Sandhu JS, Bhashyam S, Brockman JA, Breyer BN, Davis NG, Foster HE, et al. Surgical management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA guideline amendment 2023. J Urol. 2023;210:725\u201336.","journal-title":"J Urol"}],"container-title":["International Journal of Impotence Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41443-026-01271-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41443-026-01271-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41443-026-01271-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T10:02:35Z","timestamp":1776679355000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41443-026-01271-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,20]]},"references-count":84,"alternative-id":["1271"],"URL":"https:\/\/doi.org\/10.1038\/s41443-026-01271-2","relation":{},"ISSN":["0955-9930","1476-5489"],"issn-type":[{"value":"0955-9930","type":"print"},{"value":"1476-5489","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,20]]},"assertion":[{"value":"19 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ege Can Serefoglu serves as a medical speaker for Rigicon, Viatris, and Virility. He holds stock in Virility. He is also the Editor in Chief of the International Journal of Impotence Research. Other authors declare no conflicts of interest. No funding was received for this study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}